US Pharma MarketingThe post Silence’s stock soars on divesiran’s Phase II polycythaemia vera success appeared first on Clinical Trials Arena.
Silence’s stock soars on divesiran’s Phase II polycythaemia vera success
If Silence's divesiran reaches the PV market, it could become the first siRNA therapy in an indication dominated by Jakafi and Besremi. The post Silence’s stock soars on divesiran’s Phase II polycythaemia vera success appeared first on Clinical Trials Arena .
If Silence's divesiran reaches the PV market, it could become the first siRNA therapy in an indication dominated by Jakafi and Besremi.
Source: Clinical Trials Arena